(Hypertension. 2001;37:322.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the First Department of Internal Medicine (M.O., S.K., T.Y., Y.O., Y.R., N.I., K.-I.H., M.Y.) and the First Department of Pathology (Y.H., H.I.), Kobe University School of Medicine, Kobe, Japan.
Correspondence to Seinosuke Kawashima, The First Department of Internal Medicine, Kobe University School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. E-mail kawashim{at}med.kobe-u.ac.jp
| Abstract |
|---|
|
|
|---|
Key Words: nitric oxide nitric oxide synthase hypoxia hypertension, experimental remodeling
| Introduction |
|---|
|
|
|---|
Nitric oxide (NO) synthesized by endothelial NO synthase (eNOS) is a potent vasodilator and is considered to play an important role in regulating pulmonary vascular tone. In recent studies of gene-engineered mice, eNOS-deficient mice showed mild pulmonary hypertension,4 and chronic hypoxia augmented the increase in pulmonary arterial pressure and pulmonary vascular remodeling.5 6 Therefore, the reduced production of eNOS-derived NO causes pulmonary hypertension and aggravates pathophysiological conditions. NO produced by eNOS is thought to serve as a protective factor against hypoxia in the pulmonary vasculature. Although endothelium-dependent vasodilatory response is shown to be impaired in pulmonary hypertension, there are inconsistent reports on the expression of eNOS in the vessels in pulmonary hypertension.7 8 9 10 Regarding experimental hypoxia-induced pulmonary hypertension, most studies demonstrated the upregulation of eNOS in pulmonary arteries.9 11 Therefore, it is considered that upregulation of eNOS is not sufficient for overcoming the detrimental effects of chronic hypoxia on pulmonary vasculature. Although inhaled NO and gene transfer of eNOS into the lung were demonstrated to inhibit hypoxic vasoconstriction,12 13 it is still unclear whether overproduction of endogenous eNOS-derived NO can prevent pulmonary vascular remodeling and right ventricular hypertrophy associated with pulmonary hypertension.
We have reported previously that eNOS-overexpressing (eNOS-Tg) mice showed systemic hypotension caused by overproduction of NO derived from the endothelium.14 In these eNOS-Tg mice, eNOS protein levels and activity are significantly elevated in the lung compared with wild-type (WT) mice. This study was undertaken to examine the effects of endogenous NO overproduction on chronic hypoxiainduced pulmonary hypertension and vascular remodeling in eNOS-Tg mice.
| Methods |
|---|
|
|
|---|
-nitro-L-arginine
methyl ester (L-NAME), a potent inhibitor of NO synthase,
was administered in drinking water (1 mg/mL) 1week before normoxic or
hypoxic exposure and continued throughout the experimental period (4
weeks). All animal experiments were conducted according to the
Guidelines for Animal Experimentation at Kobe University School of
Medicine.
Hemodynamic
Measurements
After 3 weeks of hypoxic or normoxic exposure, mice
were weighed and anesthetized with sodium pentobarbital (80
µg/kg IP). A tracheotomy was performed, and the animal was
mechanically ventilated (Harvard small animal ventilator model 687)
with 10% O2 for the hypoxic group and with room
air for the normoxic group.4
For measuring systemic arterial pressure (SAP), a catheter
was introduced into right femoral artery as described
previously.14 After the
chest was opened, a 27-gauge stainless steel needle attached to a
pressure transducer was inserted directly into the right ventricle to
measure right ventricular systolic pressure (RVSP)
as an estimate of pulmonary arterial
systolic pressure.5
SAP, RVSP, and heart rate (HR) were recorded on a Macintosh
computer with the MacLab system (Bioresearch
Center).
Tissue Preparation, Weight Analysis,
and Hematocrit Analysis
After measurement of hemodynamic
parameters, total blood was collected from the right
ventricles and hematocrit values were obtained. The lung was removed
and rinsed with PBS, blotted dry, and weighed. The heart was resected,
both atria were removed, and the RV free wall was separated from the
left ventricle and septum. Each of the ventricles was rinsed with PBS,
blotted, and weighed.
Analysis of NOS Protein and Measurement
of Pulmonary cGMP Levels
To examine the expression of eNOS protein in the
lung, immunoblot analysis was performed with the
use of a polyclonal anti-eNOS antibody (Transduction Laboratories),
which recognizes both bovine and murine eNOS
protein.14 NOS enzymatic
activity was measured by the conversion of
[3H]-L-arginine
to
[3H]-L-citrulline,14
and lung cGMP levels were measured with an enzyme immunoassay kit
(Amersham) as described
previously.12
Measurement of Plasma and Pulmonary
ET-1 Protein Levels
In 5 to 7 animals of each group, plasma and lung ET-1
protein was extracted with a Seppak C-18 column (Waters) and measured
with a sandwich enzyme immunoassay kit (Peninsula Laboratories) as
described
previously.15
Morphological Examination (Immunohistochemistry
and Image Analysis)
To examine the vascular structural alterations and
the expression of inducible NOS (iNOS), immunohistochemical staining
was carried out by the labeled streptavidin biotin method with a
monoclonal antibody against human smooth muscle actin (DAKO A/S) or a
polyclonal antibody against mouse iNOS (Santa Cruz),
respectively.12 17
Muscularization of peripheral arterioles was determined in the lung sections of 7 to 8 animals from each group as described previously.16 All pulmonary arterioles with the external diameter of <100 µm were counted and classified by circumferential staining with actin as nonmuscular, partially muscular (<75%), or completely muscular arterioles (>75%). For each animal, at least 100 arterioles from each lung were characterized. Furthermore, the wall thickness of the media was measured along the shortest curvature for all the muscularized vessels with an external diameter of 15 to 80 µm, 80 to 150 µm, and >150 µm, respectively.2 17 Approximately 50 vessels per animal were measured. All morphometric measurements were performed by 2 independent researchers operating in a blinded manner. Interobserver difference in the measurements was <5%.
Statistical Analysis
All values are expressed as mean±SEM. Two-way ANOVA
was used to compare the differences among groups, and Bonferronis
test was used for post hoc analysis. A value of
P<0.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
|
Because hypoxic exposure is reported to upregulate the iNOS gene in pulmonary artery endothelial cells and SMC,11 immunohistochemistry for iNOS was performed and Ca2+-independent NOS activity in the cytosolic fraction of the lung homogenates was measured. The immunostaining of iNOS was, however, not detected in either group exposed to hypoxia for 3 weeks. Ca2+-independent NOS activity in the lung was also very low at the basal levels and showed minimal changes by chronic hypoxia in both groups (data not shown).
Pulmonary cGMP contents in eNOS-Tg mice were 3 times as high as those in WT mice under normoxic conditions (Figure 1C). No significant increases were observed in either genotype exposed to hypoxia compared with those exposed to normoxia.
Prevention of Hypoxia-Induced Increases
in RVSP in eNOS-Tg Mice
Under normoxic conditions, RVSP in eNOS-Tg mice was
similar to that in WT mice
(Figure 2A and
Table).
After 3 weeks of hypoxia, RVSP was elevated in both groups, but
the increase was significantly smaller in eNOS-Tg mice. Heart rate was
not significantly different between eNOS-Tg mice and WT mice exposed to
chronic hypoxia
(Figure 2B). Under anesthesia, SAP in eNOS-Tg
mice was 6 mm Hg lower than that in WT mice under normoxic
conditions, and chronic hypoxia did not change SAP in either
group
(Table).
L-NAME increased RVSP to
40 mm Hg in normoxic mice, and
further increases were observed by chronic hypoxic exposure in both
genotypes. However, there was no difference in RVSP between
eNOS-Tg and WT mice under either condition
(Table).
|
|
Hematocrit
Both eNOS-Tg mice and WT mice showed similar hematocrit
values under normoxic conditions (Tg, 0.41±0.01 versus WT,
0.39±0.02). Chronic hypoxic exposure resulted in a 1.5-fold increase
in hematocrit values in both groups, and there was no difference
between the 2 groups (Tg, 0.61±0.01 versus WT,
0.58±0.02).
Right Ventricular
Hypertrophy Caused by Chronic Hypoxia
To examine the extent of chronic
hypoxiainduced right ventricular
hypertrophy, the right ventricletoleft ventricle plus
septum weight ratio (RV/LV+S) and right ventricletobody weight
ratio (RV/BW) were measured. There were no significant differences in
RV weight (RVW) and these parameters between eNOS-Tg and WT
mice under normoxic conditions (RVW: Tg, n=28; 22.1±0.8 mg versus WT,
n=30; 22.6±0.8 mg,
NS)(Figure 2, C and D). After 3 weeks of hypoxia, RVW
and these parameters were increased in both groups;
however, the degree of right ventricular
hypertrophy was significantly more attenuated in eNOS-Tg
mice than in WT mice (RVW: Tg, n=28; 25.6±1.1 mg versus WT, n=30;
28.3±1.1 mg,
P<0.05).
Morphometric Analysis
Figure 3A shows the distribution of vessel types in both
conditions. After 3 weeks of hypoxia, the distributions of
peripheral muscular arterioles were increased in both
groups. The reduction of nonmuscular arterioles in NOS-Tg mice was
significantly smaller than in WT mice and the number of muscular
arterioles in eNOS-Tg mice did not increase as much as in WT mice. The
ratio of the number of muscular to nonmuscular arterioles shows that
chronic hypoxiainduced neomuscularization was significantly
attenuated in eNOS-Tg mice. L-NAME administration caused a 1.9-fold
increase in muscularized arterioles in normoxic WT mice and a 1.8-fold
increase in normoxic eNOS-Tg mice. Similarly, L-NAME caused a 1.3-fold
increase in muscularized arterioles in hypoxic WT mice and a 1.5-fold
increase in hypoxic eNOS-Tg mice compared with the untreated hypoxic
mouse. Consequently, the difference in distribution of muscularized
arterioles between hypoxic WT mice and hypoxic eNOS-Tg mice disappeared
by L-NAME treatment.
|
As shown in Figure 4, the wall thickness of pulmonary vessels with external diameters of 80 to 150 µm and >150 µm were increased similarly by chronic hypoxia in the two genotypes. However, medial wall thickness of pulmonary vessels with the smallest external diameter was significantly reduced in eNOS-Tg mice than that in WT mice. In additional experiments, medial wall thickness in small pulmonary arteries was measured in both groups of mice treated with L-NAME. L-NAME induced increases in wall thickening to a similar extent in WT mice (+10% increases from that in nontreated normoxic WT mice) and eNOS-Tg mice (+12% increases from that in nontreated normoxic eNOS-Tg mice). Furthermore, L-NAME treatment canceled the difference in hypoxia-induced wall thickening between WT and eNOS-Tg mice.
|
ET-1 Levels in Lung and Plasma
Because the increased production of ET-1 in the
lung and plasma is suggested to be involved in the mechanisms of
pulmonary hypertension, ET-1 levels were measured. Lung ET-1
levels in eNOS-Tg mice were similar to those in WT mice in normoxia
(Tg, 0.41±0.08 ng/mg protein versus WT, 0.70±0.16 ng/mg protein, NS).
Chronic hypoxia elevated ET-1 levels in the lung of each group.
However, there was no difference in the increase of ET-1 levels between
eNOS-Tg mice and WT mice (Tg, 1.80±0.20 ng/mg protein versus WT,
2.11±0.34 ng/mg protein,
P=NS). Plasma concentrations of
ET-1 were also increased in both groups exposed to chronic
hypoxia; however ET-1 levels in eNOS-Tg mice were not
significantly different compared with WT mice (Tg, 0.90±0.05 to
1.85±0.13 pg/mL versus WT, 0.81±0.11 to 1.75±0.05 pg/mL,
NS).
| Discussion |
|---|
|
|
|---|
In hemodynamic analysis, both eNOS-Tg mice and WT mice exposed to hypoxia for 3 weeks showed increases in RVSP. The increase in eNOS-Tg mice was significantly lower than that in WT mice. L-NAME treatment canceled the difference in RVSP between WT and eNOS-Tg mice both exposed to chronic hypoxia. The effect of NO on pulmonary vascular tone exposed to acute hypoxic stress has been well investigated. In addition to the beneficial effects of inhaled NO gas in the management of some forms of pulmonary hypertension,18 recent experimental studies demonstrated that gene transfer of eNOS into the lung attenuated pulmonary vasopressor responses to acute hypoxia.12 13 Although the present findings are in accordance with these studies in that vasopressor response to hypoxia is prevented by overproduction of endogenous NO, the elevation of RVSP (which presumably reflects pulmonary arterial systolic pressure) induced by chronic hypoxia is caused not only by vasoconstriction but by vascular remodeling of pulmonary arteries. Therefore, we further examined the protective effects of endogenous NO on hypoxia-induced alterations in pulmonary vascular beds.
In this study, eNOS protein levels and Ca2+-dependent NOS activity in eNOS-Tg mice were significantly higher than those in WT mice in normoxia and 3 weeks after hypoxia. Moreover, cGMP contents in the lung were also higher in eNOS-Tg mice compared with WT mice in both normoxic and chronic hypoxic conditions. Although it has been reported that endothelial dysfunction contributes to various forms of pulmonary hypertension in both humans and animals,8 WT mice showed a small increase in eNOS protein levels, and NOS activity and cGMP levels in the lung did not decrease after hypoxic exposure. Therefore, hypoxic exposure for 3 weeks did not impair the production of eNOS protein and its activity in the endothelium of pulmonary artery, and it is considered that the increases of NO production and subsequent cGMP production in the lung of eNOS-Tg mice may contribute to the attenuation of the RVSP elevation.
In normoxic conditions, RVSP in eNOS-Tg mice was similar to that in WT mice. This finding is different from a recent study of eNOS-deficient mice showing that mild pulmonary hypertension under normoxic conditions is caused by elevated pulmonary vascular resistance.4 However, there are redundant vasoactive substances modulating pulmonary circulation, and NO alone is not sufficient to control basal vascular tone. Therefore, the present finding is not contradictory to the study in eNOS-deficient mice.
Chronic hypoxic exposure causes pulmonary vascular remodeling characterized by proliferation and migration of SMC as well as an increased accumulation of extracellular matrix.19 In the histological analysis, this study demonstrated the increases of medial wall thickness in pulmonary arteries and the increases of neomuscularized arterioles in chronic hypoxia. However, medial wall thickening in pulmonary small vessels was attenuated and the number of neomuscularized arteries was reduced in eNOS-Tg mice. Moreover, NOS inhibition with L-NAME canceled the amelioration of pulmonary vascular structural changes in eNOS-Tg mice. These findings agree with the recent reports in which the administration of the NO precursor L-arginine and chronic NO gas inhalation could ameliorate the vascular structural changes induced by hypoxia.17 20 However, our study extended those studies in that overproduction of eNOS-derived NO inhibited pulmonary vascular remodeling.
One possible explanation for the improvement of pulmonary vascular remodeling is the direct action of NO on nearby vascular SMC through cGMP-dependent pathways. cGMP has been proposed to inhibit the mitogenesis and proliferation in cultured rat SMC,21 and cGMP-dependent protein kinase is also reported to inhibit proliferation of SMC in the pulmonary artery.22 Furthermore, the reduced mechanical stress in pulmonary vasculature of eNOS-Tg mice was probably involved in the improvement of vascular structural alterations. Because mechanical stress promotes SMC proliferation by inducing Ca2+ influx and increases growth factor expression,23 the reduced RVSP in eNOS-Tg mice might partly participate in the amelioration of pulmonary vascular remodeling.
Several factors are considered to be involved as modulators or mediators of the vascular structural alterations induced by hypoxic pulmonary hypertension. Among those factors, ET-1 is a potent endothelium-derived vasoconstrictor peptide with mitogenic effects on vascular SMC and is suggested to be involved in the development of pulmonary hypertension.24 Because it is proposed that ET-1 and NO function to regulate each others level during hypoxia25 and NO has been shown to inhibit the expression of ET-1 induced by hypoxia,26 ET-1 levels were examined in the lung and plasma under both normoxic and hypoxic conditions. However, ET-1 levels and the degree of their increases by hypoxia in the lung and plasma were not significantly different between the two genotypes. In this study, it is difficult to clarify the interaction of NO and ET-1 because of the use of ppET-1 promoter in the transgene of eNOS-Tg mice. However, it seems unlikely that the inhibitory effects of NO in increase in RVSP and pulmonary vascular remodeling are mediated by its action in ET-1 production.
As a limitation in this study, we used RVSP as an estimate of pulmonary systolic pressure. Measurements of RVSP without taking transpulmonary pressure into account in the presence of positive-pressure ventilation may not reflect the real pulmonary systolic pressure. However, the comparison of RVSP between two genotypes successfully provide us the beneficial effects of eNOS-derived NO on pulmonary vascular beds.
In conclusion, we demonstrated in eNOS-Tg mice that not only the increases in RVSP but also pulmonary vascular remodeling and right ventricular hypertrophy induced by chronic hypoxia were attenuated by chronic increases of NO production in the endothelium of pulmonary vessels. Recent studies demonstrated the importance of therapeutic strategy toward increasing endothelial NO availability in the treatment of various vascular disorders. At present, there have been no reports investigating whether pharmacological manipulations can prevent or improve pulmonary hypertension and pulmonary vascular remodeling by increasing eNOS activity or protein expression. The present study shows the protective role of endogenous NO in the pathogenesis of chronic hypoxic pulmonary hypertension in vivo and implies that upregulation of eNOS or an increase of endogenous NO production can serve as important means for treatment of pulmonary hypertension.
| Acknowledgments |
|---|
Received March 8, 2000; first decision March 30, 2000; accepted August 4, 2000.
| References |
|---|
|
|
|---|
2. Rabinovitch M, Bothwell T, Hayakawa BN, Williams WG, Trusler GA, Rowe RD, Olley PM, Cutz E. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: a correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest. 1986;55:632653.[Medline] [Order article via Infotrieve]
3. Stenmark KR, Mecham RP. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol. 1997;59:89144.[Medline] [Order article via Infotrieve]
4.
Steudel W, Ichinose
F, Huang PL, Hurford WE, Jones RC, Bevan JA, Fishman MC, Zapol WM.
Pulmonary vasoconstriction and hypertension in mice with
targeted disruption of the endothelial nitric oxide
synthase (NOS 3) gene. Circ
Res. 1997;81:3441.
5. Steudel W, Scherrer CM, Bloch KD, Weimann J, Huang PL, Jones RC, Picard MH, Zapol WM. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest. 1998;101:24682477.[Medline] [Order article via Infotrieve]
6. Fagan KA, Fouty BW, Tyler RC, Morris KG, Hepler LK, Sato K, LeCras TD, Abman SH, Weinberger HD, Huang PL, McMurty IF, Rodman DM. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest. 1999;103:291299.[Medline] [Order article via Infotrieve]
7. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest. 1991;87:155162.
8.
Giaid A, Saleh D.
Reduced expression of endothelial nitric oxide synthase
in the lungs of patients with pulmonary hypertension.
N Engl J Med. 1995;333:214221.
9.
Resta TC, Gonzales
RJ, Dail WG, Sanders TC, Walker BR. Selective upregulation of
arterial endothelial nitric oxide synthase
in pulmonary hypertension. Am
J Physiol. 1997;272:H806H813.
10. Mason NA, Springall DR, Burke M, Pollock J, Mikhail G, Yacoub MH, Polak JM. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol. 1998;185:313318.[Medline] [Order article via Infotrieve]
11.
Xue C, Johns RA.
Upregulation of nitric oxide synthase correlates temporally with onset
of pulmonary vascular remodeling in the hypoxic rat.
Hypertension. 1996;28:743753.
12. Janssens SP, Bloch KD, Nong Z, Gerard RD, Zoldhelyi P, Collen D. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest. 1996;98:317324.[Medline] [Order article via Infotrieve]
13.
Champion HC,
Bivalacqua TJ, DSouza FM, Ortiz LA, Jeter JR, Toyoda K, Heistad DD,
Hyman AL, Kadowitz PJ. Gene transfer of
endothelial nitric oxide synthase to the lung of the
mouse in vivo: effect on agonist-induced and flow-mediated vascular
responses. Circ Res. 1999;84:14221432.
14. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, Yokoyama M. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest. 1998;102:20612071.[Medline] [Order article via Infotrieve]
15.
Cacoub P, Dorent
R, Nataf P, Carayon A, Riquet M, Noe E, Piette JC, Godeau P,
Gandjbakhch I. Endothelin-1 in the lungs of patients with
pulmonary hypertension. Cardiovasc
Res. 1997;33:196200.
16. Meyrick B, Reid L. The effect of chronic hypoxia on pulmonary arteries in young rats. Exp Lung Res. 1981;2:257271.[Medline] [Order article via Infotrieve]
17.
Roos CM, Frank
DU, Xue C, Johns RA, Rich GF. Chronic inhaled nitric oxide: effects on
pulmonary vascular endothelial function and
pathology in rats. J Appl
Physiol. 1996;80:252260.
18. Zapol WM, Rimar S, Gillis N, Marletta M, Bosken CH. Nitric oxide and the lung. Am J Respir Crit Care Med. 1994;149:13751380.[Medline] [Order article via Infotrieve]
19. Meyrick B, Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation: an ultrastructural study. Lab Invest. 1978;38:188200.[Medline] [Order article via Infotrieve]
20.
Mitani Y,
Maruyama K, Sakurai M. Prolonged administration of L-arginine
ameliorates chronic pulmonary hypertension and
pulmonary vascular remodeling in rats.
Circulation. 1997;96:689697.
21. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:17741777.
22.
Chiche JD,
Schlutsmeyer SM, Bloch DB, Monte SM, Roberts JD, Filippov G, Janssens
SP, Rosenzweig A, Bloch KD. Adenovirus-mediated gene transfer of
cGMP-dependent protein kinase increases the sensitivity of cultured
vascular smooth muscle cells to the antiproliferative and
pro-apoptotic effects of nitric oxide/cGMP.
J Biol Chem. 1998;273:3426334271.
23.
Wilson E, Mai Q,
Sudhir K, Weiss RH, Ives HE. Mechanical strain induces growth of
vascular smooth muscle cells via autocrine action of PDGF.
J Cell Biol. 1993;123:741747.
24.
Giaid A,
Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S,
Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the
lungs of patients with pulmonary hypertension.
N Engl J Med. 1993;328:17321739.
25. Fagan JM, Rex SE, Hayes LS, Waxman L. L-arginine reduces right heart hypertrophy in hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun. 1999;254:100103.[Medline] [Order article via Infotrieve]
26. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 1993;92:99104.
This article has been cited by other articles:
![]() |
R. P. Weerackody, D. J. Welsh, R. M. Wadsworth, and A. J. Peacock Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1312 - H1320. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xu, O. Platoshyn, A. Makino, W. H. Dillmann, K. Akassoglou, C. V. Remillard, and J. X.-J. Yuan Characterization of agonist-induced vasoconstriction in mouse pulmonary artery Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H220 - H228. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pokreisz, G. Marsboom, and S. Janssens Pressure overload-induced right ventricular dysfunction and remodelling in experimental pulmonary hypertension: the right heart revisited Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H75 - H84. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Fish, C. C. Matouk, E. Yeboah, S. C. Bevan, M. Khan, K. Patil, M. Ohh, and P. A. Marsden Hypoxia-inducible Expression of a Natural cis-Antisense Transcript Inhibits Endothelial Nitric-oxide Synthase J. Biol. Chem., May 25, 2007; 282(21): 15652 - 15666. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takenaka, Y. Nishimura, T. Nishiuma, A. Sakashita, T. Yamashita, K. Kobayashi, M. Satouchi, T. Ishida, S. Kawashima, and M. Yokoyama Ventilator-induced lung injury is reduced in transgenic mice that overexpress endothelial nitric oxide synthase Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1078 - L1086. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Hoit, N. D. Dalton, S. C. Erzurum, D. Laskowski, K. P. Strohl, and C. M. Beall Nitric oxide and cardiopulmonary hemodynamics in Tibetan highlanders J Appl Physiol, November 1, 2005; 99(5): 1796 - 1801. [Abstract] [Full Text] [PDF] |
||||
![]() |
J L Wright, R D Levy, and A Churg Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment Thorax, July 1, 2005; 60(7): 605 - 609. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Kobs, N. E. Muvarak, J. C. Eickhoff, and N. C. Chesler Linked mechanical and biological aspects of remodeling in mouse pulmonary arteries with hypoxia-induced hypertension Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1209 - H1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ishida, S. Y. Choi, R. K. Kundu, J. Spin, T. Yamashita, K.-i. Hirata, Y. Kojima, M. Yokoyama, A. D. Cooper, and T. Quertermous Endothelial Lipase Modulates Susceptibility to Atherosclerosis in Apolipoprotein-E-deficient Mice J. Biol. Chem., October 22, 2004; 279(43): 45085 - 45092. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Fagan, M. Oka, N. R. Bauer, S. A. Gebb, D. D. Ivy, K. G. Morris, and I. F. McMurtry Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L656 - L664. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. L. M. Ricciardolo, P. J. Sterk, B. Gaston, and G. Folkerts Nitric Oxide in Health and Disease of the Respiratory System Physiol Rev, July 1, 2004; 84(3): 731 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Budhiraja, R. M. Tuder, and P. M. Hassoun Endothelial Dysfunction in Pulmonary Hypertension Circulation, January 20, 2004; 109(2): 159 - 165. [Full Text] [PDF] |
||||
![]() |
S. M. Lowson Nitric Oxide Signaling and Clinical Alternatives to Nitric Oxide Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 239 - 252. [Abstract] [PDF] |
||||
![]() |
F L M Ricciardolo Multiple roles of nitric oxide in the airways Thorax, February 1, 2003; 58(2): 175 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Ashrafian and L Swan The mechanism of formation of pulmonary arteriovenous malformations associated with the classic Glenn shunt (superior cavopulmonary anastomosis) Heart, December 1, 2002; 88(6): 639 - 639. [Full Text] [PDF] |
||||
![]() |
H. C. Champion, T. J. Bivalacqua, S. S. Greenberg, T. D. Giles, A. L. Hyman, and P. J. Kadowitz Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice PNAS, October 1, 2002; 99(20): 13248 - 13253. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takemoto, J. Sun, J. Hiroki, H. Shimokawa, and J. K. Liao Rho-Kinase Mediates Hypoxia-Induced Downregulation of Endothelial Nitric Oxide Synthase Circulation, July 2, 2002; 106(1): 57 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Corno, G. Milano, M. Samaja, P. Tozzi, and L. K. von Segesser Chronic hypoxia: A model for cyanotic congenital heart defects J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 105 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ozaki, S. Kawashima, T. Hirase, T. Yamashita, M. Namiki, N. Inoue, K.-i. Hirata, and M. Yokoyama Overexpression of Endothelial Nitric Oxide Synthase in Endothelial Cells Is Protective against Ischemia-Reperfusion Injury in Mouse Skeletal Muscle Am. J. Pathol., April 1, 2002; 160(4): 1335 - 1344. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Earley, L. D. Nelin, L. G. Chicoine, and B. R. Walker Hypoxia-induced pulmonary endothelin-1 expression is unaltered by nitric oxide J Appl Physiol, March 1, 2002; 92(3): 1152 - 1158. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |